GlassScriptPhysician profile
Michael John Norgard
NPI 1568584670
$389.23
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $63.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $66.77 | 2019-2020 | |
| Pfizer INC. | $61.22 | 2019 | |
| Merck Sharp & Dohme LLC | $31.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $19.02 | 2019 | |
| Incyte Corporation | $17.52 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.66 | 2019 | |
| Gilead Sciences, INC. | $15.56 | 2019 | |
| Clovis Oncology, INC. | $15.35 | 2019 | |
| Lilly USA, LLC | $14.62 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Norgard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.